LSP has raised $330 million for its second medical technology fund. The big jump in size over the first fund tees up LSP to place bets on 15 companies with close-to-market devices, diagnostics and digital health tools.
Approval based on data from the Phase III RESORCE study where Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib)
Contrary to popular belief, and the opinions of many women, men really do suffer from 'man flu,' at least according to a Canadian researcher and his most recent study.
A DNA double helix is seen in an undated artist's illustration released by the National Human Genome Research Institute to Reuters on May 15, 2012. REUTERS/National Human Genome Research Institute/Handout.
The team has unveiled a neural stimulator that is less than a cubic millimeter in size that can be placed directly where desired and that is powered using an external induction-based system.
The light-sensitive layer found at the back of a person's eyes contains more than just cells that detect shadows and light — it also contains information about the health of a person's entire body. And now, artificial intelligence can glean this information from a single snapshot, new research suggests.
The U.S. Food and Drug Administration(FDA) approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. Admelog is the first short-acting insulin approved as a “follow-on” product (submitted through the agency’s 505(b)(2) pathway).
Pfizer has won a first approval for OTC Viagra. Viagra Connect, the Pfizer OTC name for its blockbuster erectile dysfunction drug, has been approved for sale in the U.K.
Singapore-based health analytics platform Biofourmis announced the close of its series A funding round, while also unveiling a partnership with US medical research institute, the Mayo Clinic.
A world-first dengue vaccination programme in the Philippines that was suspended over safety concerns will not cause anyone who was immunised to die, drug manufacturer Sanofi and local authorities said on Monday
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.